ESMO 24: Nuvation One Step Ahead In Race For ROS1 Lung Cancer Niche
Two similarly named companies, Nuvation and Nuvalent, are racing to see who can claim best-in-class status in next-generation lung cancer therapies.
Two similarly named companies, Nuvation and Nuvalent, are racing to see who can claim best-in-class status in next-generation lung cancer therapies.